All In Biotech

Drug Trial Radar · NCT01954316

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer

Last checked: Nov 20, 2026Latest source record: Jan 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Mar 2014

Primary completion

Jul 2021

Study completion Jul 22, 2021

Sponsor

Lead sponsor
University Health Network, TorontoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Princess Margaret Cancer Foundation; California Institute for Regenerative Medicine (CIRM)
First posted
Oct 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 study to test different doses of a new investigational drug called CFI-400945 to see which dose is safer in people. This study will also look at the safety of CFI-400945 and to study its effects on patients with advanced cancers. This drug has been tested in animals but not yet in people. CFI-400945 is an oral (taken by mouth) drug that works by blocking polo-like kinase 4 (PLK4) from working. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to lead to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors growing or shrink them.

Conditions

  • Advanced Cancer

Interventions

  • CFI-400945Drug

    Polo-like kinase 4 (PLK4) inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Highest dose level that does not lead to unacceptable toxicity in two or more patients in a dosing group over a range of doses and schedulesTime frame: From first dose of study drug until the date of unacceptable toxicity, throughout the study completion, up to 2 years

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Santa Monica, California

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.